Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Compass Therapeutics, Inc. (CMPX)
Company Research
Source: GlobeNewswire
CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies.In vivo, CTX-10726 outperformed select competitive antibodies in the class, including ivonescimab, in controlling tumor growth across multiple xenograft and syngeneic models.IND submission is on track for Q4 2025. BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 5-9, 2025, in National Harbor, MD. Details of the presentation are as follows: Title: Preclinical Development of CTX-10726, a Tetravalent Bispecific Antibody Targeting PD-1 and VEGF-A for the Treatment of Patients with CancerPresenter: Diana Albu, PhD; Compass TherapeuticsDate &
Show less
Read more
Impact Snapshot
Event Time:
CMPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMPX alerts
High impacting Compass Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CMPX
News
- Compass Therapeutics, Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Compass Therapeutics (NASDAQ:CMPX) is now covered by analysts at Citizens Jmp. They set an "outperform" rating and a $10.00 price target on the stock.MarketBeat
- Compass Therapeutics (NASDAQ:CMPX) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
- Compass Therapeutics (NASDAQ:CMPX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.MarketBeat
- Compass Therapeutics (NASDAQ:CMPX) was given a new $10.00 price target on by analysts at JMP Securities.MarketBeat
CMPX
Earnings
- 8/11/25 - Miss
CMPX
Sec Filings
- 11/18/25 - Form 4
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- CMPX's page on the SEC website